spartalizumab + LAG525 + capmatinib

A combination therapy consisting of three agents: **spartalizumab** (a humanized monoclonal antibody targeting PD-1, an immune checkpoint inhibitor), **LAG525** (a monoclonal antibody targeting LAG-3, another immune checkpoint molecule), and **capmatinib** (a small molecule inhibitor of the c-Met receptor tyrosine kinase). This regimen is designed to combine immune checkpoint blockade (PD-1 and LAG-3) with targeted inhibition of MET signaling, aiming to enhance anti-tumor immune activity and directly inhibit MET-driven tumor growth and survival. Each component has demonstrated potential in treating solid tumors, especially in oncology settings where PD-1, LAG-3, and MET pathways contribute to tumor immune evasion and cancer cell proliferation[1][2][7].